Dajia Weikang released its 2026 interim report. The company's total operating revenue was 2.702 billion yuan, down 0.25% from the same period last year, and net profit attributable to the parent company was 7.2565 million yuan. Net cash inflow from operating activities was 11.4727 million yuan, the asset-liability ratio was 74.42%, gross margin was 18.30%, ROE was 0.49%, and diluted earnings per share was 0.04 yuan. The company had 13,600 shareholders, and the top ten shareholders held 55.89% of the total share capital.
Hunan Dajiaweikang Pharmaceutical Industry Co.LtdNet profit of 7.2565 million yuan is extremely low relative to revenue, indicating weak profitability.